Mill Capital Management LLC Sells 5,259 Shares of Pfizer Inc. (NYSE:PFE)

Mill Capital Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,905 shares of the biopharmaceutical company’s stock after selling 5,259 shares during the period. Mill Capital Management LLC’s holdings in Pfizer were worth $4,906,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

Pfizer stock opened at $26.20 on Monday. The firm has a 50 day moving average of $26.17 and a 200 day moving average of $27.04. The firm has a market capitalization of $148.61 billion, a price-to-earnings ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PFE shares. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.